Low FODMAP Diet and Probiotics in Irritable Bowel Syndrome: A Systematic Review With Network Meta-analysis
Background: Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probioti...
Saved in:
Published in | Frontiers in pharmacology Vol. 13; p. 853011 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
09.03.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background:
Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probiotics or low FODMAP diet through component network meta-analysis (NMA).
Methods:
We searched Embase, Ovid Medline, and Web of Science from inception to 21 January 2021. Randomized controlled trials (RCTs) examining the efficacy of probiotics and low FODMAP diet for IBS were included, with placebo, sham diet, or conventional treatments as controls. Binary outcomes were compared among treatments using the relative ratio (RR). A minimally contextualized framework recommended by the GRADE group was used to evaluate the certainty of evidence. The primary efficacy outcome was the relief of global IBS symptoms, and the secondary efficacy outcome was the reduction in IBS symptom scores or abdominal pain scores.
Key Results:
We included 76 RCTs (n = 8058) after screening 1940 articles. Eight RCTs were classified as low risk of bias. Standard network meta-analysis (NMA) showed that
Lactobacillus
(RR 1.74, 95% CI 1.22–2.48) and
Bifidobacterium
(RR 1.76, 95% CI 1.01–3.07) were the most effective for the primary efficacy outcome (high certainty evidence); component NMA showed that
Bacillus
(RR 5.67, 95% CI 1.88 to 17.08,
p
= 0.002) and
Lactobacillus
(RR 1.42, 95% CI 1.07 to 1.91,
p
= 0.017) were among the most effective components. The results of standard NMA and CNMA analysis of the improvement of overall IBS symptom scores or abdominal pain scores were consistent with this finding.
Conclusion:
Lactobacillus
was the most effective component for the relief of IBS symptoms;
Bifidobacterium
and
Bacillus
were possibly effective and need further verification.
Systematic Review Registration:
website, identifier registration number. |
---|---|
AbstractList | Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probiotics or low FODMAP diet through component network meta-analysis (NMA).
We searched Embase, Ovid Medline, and Web of Science from inception to 21 January 2021. Randomized controlled trials (RCTs) examining the efficacy of probiotics and low FODMAP diet for IBS were included, with placebo, sham diet, or conventional treatments as controls. Binary outcomes were compared among treatments using the relative ratio (RR). A minimally contextualized framework recommended by the GRADE group was used to evaluate the certainty of evidence. The primary efficacy outcome was the relief of global IBS symptoms, and the secondary efficacy outcome was the reduction in IBS symptom scores or abdominal pain scores.
We included 76 RCTs (n = 8058) after screening 1940 articles. Eight RCTs were classified as low risk of bias. Standard network meta-analysis (NMA) showed that
(RR 1.74, 95% CI 1.22-2.48) and
(RR 1.76, 95% CI 1.01-3.07) were the most effective for the primary efficacy outcome (high certainty evidence); component NMA showed that
(RR 5.67, 95% CI 1.88 to 17.08,
= 0.002) and
(RR 1.42, 95% CI 1.07 to 1.91,
= 0.017) were among the most effective components. The results of standard NMA and CNMA analysis of the improvement of overall IBS symptom scores or abdominal pain scores were consistent with this finding.
was the most effective component for the relief of IBS symptoms;
and
were possibly effective and need further verification.
website, identifier registration number. Background: Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probiotics or low FODMAP diet through component network meta-analysis (NMA).Methods: We searched Embase, Ovid Medline, and Web of Science from inception to 21 January 2021. Randomized controlled trials (RCTs) examining the efficacy of probiotics and low FODMAP diet for IBS were included, with placebo, sham diet, or conventional treatments as controls. Binary outcomes were compared among treatments using the relative ratio (RR). A minimally contextualized framework recommended by the GRADE group was used to evaluate the certainty of evidence. The primary efficacy outcome was the relief of global IBS symptoms, and the secondary efficacy outcome was the reduction in IBS symptom scores or abdominal pain scores.Key Results: We included 76 RCTs (n = 8058) after screening 1940 articles. Eight RCTs were classified as low risk of bias. Standard network meta-analysis (NMA) showed that Lactobacillus (RR 1.74, 95% CI 1.22–2.48) and Bifidobacterium (RR 1.76, 95% CI 1.01–3.07) were the most effective for the primary efficacy outcome (high certainty evidence); component NMA showed that Bacillus (RR 5.67, 95% CI 1.88 to 17.08, p = 0.002) and Lactobacillus (RR 1.42, 95% CI 1.07 to 1.91, p = 0.017) were among the most effective components. The results of standard NMA and CNMA analysis of the improvement of overall IBS symptom scores or abdominal pain scores were consistent with this finding.Conclusion:Lactobacillus was the most effective component for the relief of IBS symptoms; Bifidobacterium and Bacillus were possibly effective and need further verification.Systematic Review Registration: website, identifier registration number. Background: Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probiotics or low FODMAP diet through component network meta-analysis (NMA). Methods: We searched Embase, Ovid Medline, and Web of Science from inception to 21 January 2021. Randomized controlled trials (RCTs) examining the efficacy of probiotics and low FODMAP diet for IBS were included, with placebo, sham diet, or conventional treatments as controls. Binary outcomes were compared among treatments using the relative ratio (RR). A minimally contextualized framework recommended by the GRADE group was used to evaluate the certainty of evidence. The primary efficacy outcome was the relief of global IBS symptoms, and the secondary efficacy outcome was the reduction in IBS symptom scores or abdominal pain scores. Key Results: We included 76 RCTs (n = 8058) after screening 1940 articles. Eight RCTs were classified as low risk of bias. Standard network meta-analysis (NMA) showed that Lactobacillus (RR 1.74, 95% CI 1.22–2.48) and Bifidobacterium (RR 1.76, 95% CI 1.01–3.07) were the most effective for the primary efficacy outcome (high certainty evidence); component NMA showed that Bacillus (RR 5.67, 95% CI 1.88 to 17.08, p = 0.002) and Lactobacillus (RR 1.42, 95% CI 1.07 to 1.91, p = 0.017) were among the most effective components. The results of standard NMA and CNMA analysis of the improvement of overall IBS symptom scores or abdominal pain scores were consistent with this finding. Conclusion: Lactobacillus was the most effective component for the relief of IBS symptoms; Bifidobacterium and Bacillus were possibly effective and need further verification. Systematic Review Registration: website, identifier registration number. Background: Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probiotics or low FODMAP diet through component network meta-analysis (NMA). Methods: We searched Embase, Ovid Medline, and Web of Science from inception to 21 January 2021. Randomized controlled trials (RCTs) examining the efficacy of probiotics and low FODMAP diet for IBS were included, with placebo, sham diet, or conventional treatments as controls. Binary outcomes were compared among treatments using the relative ratio (RR). A minimally contextualized framework recommended by the GRADE group was used to evaluate the certainty of evidence. The primary efficacy outcome was the relief of global IBS symptoms, and the secondary efficacy outcome was the reduction in IBS symptom scores or abdominal pain scores. Key Results: We included 76 RCTs (n = 8058) after screening 1940 articles. Eight RCTs were classified as low risk of bias. Standard network meta-analysis (NMA) showed that Lactobacillus (RR 1.74, 95% CI 1.22-2.48) and Bifidobacterium (RR 1.76, 95% CI 1.01-3.07) were the most effective for the primary efficacy outcome (high certainty evidence); component NMA showed that Bacillus (RR 5.67, 95% CI 1.88 to 17.08, p = 0.002) and Lactobacillus (RR 1.42, 95% CI 1.07 to 1.91, p = 0.017) were among the most effective components. The results of standard NMA and CNMA analysis of the improvement of overall IBS symptom scores or abdominal pain scores were consistent with this finding. Conclusion: Lactobacillus was the most effective component for the relief of IBS symptoms; Bifidobacterium and Bacillus were possibly effective and need further verification. Systematic Review Registration: website, identifier registration number.Background: Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients with irritable bowel syndrome (IBS). We aimed to evaluate the most effective combinations and components among different probiotics or low FODMAP diet through component network meta-analysis (NMA). Methods: We searched Embase, Ovid Medline, and Web of Science from inception to 21 January 2021. Randomized controlled trials (RCTs) examining the efficacy of probiotics and low FODMAP diet for IBS were included, with placebo, sham diet, or conventional treatments as controls. Binary outcomes were compared among treatments using the relative ratio (RR). A minimally contextualized framework recommended by the GRADE group was used to evaluate the certainty of evidence. The primary efficacy outcome was the relief of global IBS symptoms, and the secondary efficacy outcome was the reduction in IBS symptom scores or abdominal pain scores. Key Results: We included 76 RCTs (n = 8058) after screening 1940 articles. Eight RCTs were classified as low risk of bias. Standard network meta-analysis (NMA) showed that Lactobacillus (RR 1.74, 95% CI 1.22-2.48) and Bifidobacterium (RR 1.76, 95% CI 1.01-3.07) were the most effective for the primary efficacy outcome (high certainty evidence); component NMA showed that Bacillus (RR 5.67, 95% CI 1.88 to 17.08, p = 0.002) and Lactobacillus (RR 1.42, 95% CI 1.07 to 1.91, p = 0.017) were among the most effective components. The results of standard NMA and CNMA analysis of the improvement of overall IBS symptom scores or abdominal pain scores were consistent with this finding. Conclusion: Lactobacillus was the most effective component for the relief of IBS symptoms; Bifidobacterium and Bacillus were possibly effective and need further verification. Systematic Review Registration: website, identifier registration number. |
Author | Xie, Chao-Rong Tao, Qing-Feng Yu, Shu-Guang Zheng, Hui Chen, Min Peng, Wen-Yan Shi, Yun-Zhou Ye, Kun Tang, Bin |
AuthorAffiliation | 1 The Third Hospital/Acupuncture and Tuina School , Chengdu University of Traditional Chinese Medicine , Chengdu , China 3 Department of Colorectal Diseases , Hospital of Chengdu University of Traditional Chinese Medicine , Chengdu University of Traditional Chinese Medicine , Chengdu , China 2 Digestive Department , People’s Hospital of Zhongjiang County , Zhongjiang , China |
AuthorAffiliation_xml | – name: 2 Digestive Department , People’s Hospital of Zhongjiang County , Zhongjiang , China – name: 3 Department of Colorectal Diseases , Hospital of Chengdu University of Traditional Chinese Medicine , Chengdu University of Traditional Chinese Medicine , Chengdu , China – name: 1 The Third Hospital/Acupuncture and Tuina School , Chengdu University of Traditional Chinese Medicine , Chengdu , China |
Author_xml | – sequence: 1 givenname: Chao-Rong surname: Xie fullname: Xie, Chao-Rong – sequence: 2 givenname: Bin surname: Tang fullname: Tang, Bin – sequence: 3 givenname: Yun-Zhou surname: Shi fullname: Shi, Yun-Zhou – sequence: 4 givenname: Wen-Yan surname: Peng fullname: Peng, Wen-Yan – sequence: 5 givenname: Kun surname: Ye fullname: Ye, Kun – sequence: 6 givenname: Qing-Feng surname: Tao fullname: Tao, Qing-Feng – sequence: 7 givenname: Shu-Guang surname: Yu fullname: Yu, Shu-Guang – sequence: 8 givenname: Hui surname: Zheng fullname: Zheng, Hui – sequence: 9 givenname: Min surname: Chen fullname: Chen, Min |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35355730$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kk1vEzEQhleoiJbSH8AF-cglwWuvP5YDUtpSiJTSig9xtMbe2cZhsw620yj_nk1TqpYDvnhkv_O8I837sjjoQ49F8bqkY851_a5dzSGOGWVsrAWnZfmsOCql5KNal-zgUX1YnKS0oMPhdc1l9aI45IILoTg9KhazsCEXV-eXk2ty7jET6BtyHYP1IXuXiO_JNEafwXZITsMGO_Jt2zcxLPE9mQx1yriEQUq-4q3HDfnp85x8wbwJ8Re5xAwj6KHbJp9eFc9b6BKe3N_HxY-Lj9_PPo9mV5-mZ5PZyFVS5BE6lK1SlEEjnWLWYkOpsBIoMLDKVUpJRZVQwKyUSteU1pq1KJoKZOVqflxM99wmwMKsol9C3JoA3tw9hHhjIA4Td2gqqkGWDlxjy0rV1tbQCuCUKQdat9XA-rBnrdZ2iY3DPkfonkCf_vR-bm7CrdG1qIViA-DtPSCG32tM2Sx9cth10GNYJ8NkJbSQpd55vXns9WDyd1mDoNwLXAwpRWwfJCU1u0yYu0yYXSbMPhNDj_qnxw3LzD7sxvXdfzr_AFbgvRQ |
CitedBy_id | crossref_primary_10_1039_D3FO03717G crossref_primary_10_3390_ijms241914562 crossref_primary_10_3390_jcm12144838 crossref_primary_10_1007_s12602_023_10151_w crossref_primary_10_3390_ijms25052550 crossref_primary_10_11569_wcjd_v30_i20_886 crossref_primary_10_3390_nu16071027 crossref_primary_10_3390_nu16111727 crossref_primary_10_1002_iid3_857 crossref_primary_10_1038_s41392_023_01673_4 crossref_primary_10_1097_MOG_0000000000000902 crossref_primary_10_70749_ijbr_v3i3_822 |
Cites_doi | 10.1136/bmj.l4898 10.1007/s10068-019-00717-2 10.1111/j.1365-2036.2011.04633.x 10.1111/j.1365-2036.2008.03853.x 10.3748/wjg.v20.i26.8709 10.1186/1471-230X-13-45 10.3748/wjg.v18.i17.2067 10.1097/MD.0000000000016068 10.3390/nu11122887 10.1155/2013/824605 10.1159/000510950 10.1016/j.nut.2017.07.004 10.1136/bmj.m3900 10.1016/j.ctim.2019.07.001 10.1111/nmo.12320 10.14309/ajg.0000000000000641 10.1053/j.gastro.2016.03.035 10.1007/s10620-007-0196-4 10.1186/s12955-017-0611-2 10.1111/j.1365-2036.2005.02579.x 10.1097/MCG.0b013e31823712b1 10.3109/02813438909103666 10.1007/s00394-020-02473-0 10.1016/j.dld.2014.11.007 10.1053/j.gastro.2016.02.031 10.3109/00365521.2013.825314 10.1111/apt.15001 10.1046/j.1365-2036.1997.142318000.x 10.1046/j.1365-2036.2003.01543.x 10.1155/2012/214102 10.1038/s41395-018-0195-4 10.3389/fphar.2020.00332 10.1053/j.gastro.2020.05.059 10.1053/j.gastro.2017.06.010 10.1016/j.gcb.2007.06.001 10.1038/s41395-018-0262-x 10.1016/j.ijsu.2020.01.142 10.1053/j.gastro.2016.02.010 10.1111/j.1572-0241.2006.00734.x 10.1111/nmo.13037 10.1053/j.gastro.2017.05.003 10.1016/j.dld.2019.12.009 10.3390/nu11091968 10.3390/nu13030756 10.1038/ajg.2014.148 10.3810/pgm.2009.03.1984 10.1038/s41598-019-48554-x 10.1002/bimj.201900339 10.1111/jgh.15410 10.3748/wjg.v22.i48.10631 10.1016/S0140-6736(20)31548-8 10.1111/jgh.12322 10.1186/1751-0759-6-16 10.1111/apt.13286 10.1111/j.1365-2036.2007.03542.x 10.1007/s00384-011-1363-9 10.3390/nu12020363 10.3748/wjg.v18.i30.4012 10.3748/wjg.v20.i43.16215 10.1111/j.1365-2982.2005.00695.x 10.1097/MEG.0000000000000094 10.1007/s10620-014-3299-8 10.1136/gutjnl-2015-311339 10.1007/s12602-010-9059-y 10.1097/00042737-200110000-00004 10.4161/gmic.24196 10.1097/MEG.0000000000000484 10.3390/nu11122856 10.1002/bimj.201800167 10.1007/s00384-019-03462-4 10.3164/jcbn.15-14 10.1136/gutjnl-2021-325214 10.1055/s-2008-1027702 10.1111/j.1365-2036.2008.03848.x 10.5009/gnl.2009.3.2.101 10.3164/jcbn.17-73 10.1111/j.1365-2036.2008.03818.x 10.3945/jn.112.159285 10.1097/MCG.0b013e318204593e 10.14309/ajg.0000000000001036 10.1016/j.clnu.2005.06.001 10.1056/NEJMra1607547 10.1016/S2468-1253(20)30056-X 10.3390/jcm10163497 10.1002/jrsm.1058 10.1038/ajg.2014.202 10.1111/apt.12787 10.1038/ajg.2016.434 10.1053/j.gastro.2020.04.014 10.1053/j.gastro.2015.07.054 10.1016/j.nut.2014.02.010 10.1046/j.1572-0241.2003.04024.x 10.1111/j.1365-2036.2007.03362.x 10.1177/2050640615602571 10.1111/j.1365-2036.2009.04183.x 10.3390/nu12041159 10.1097/MCG.0b013e31820ca4d6 10.3109/00365521.2011.565066 10.1136/gutjnl-2018-318160 10.1111/j.1572-0241.2000.02015.x 10.1097/SGA.0000000000000428 |
ContentType | Journal Article |
Copyright | Copyright © 2022 Xie, Tang, Shi, Peng, Ye, Tao, Yu, Zheng and Chen. Copyright © 2022 Xie, Tang, Shi, Peng, Ye, Tao, Yu, Zheng and Chen. 2022 Xie, Tang, Shi, Peng, Ye, Tao, Yu, Zheng and Chen |
Copyright_xml | – notice: Copyright © 2022 Xie, Tang, Shi, Peng, Ye, Tao, Yu, Zheng and Chen. – notice: Copyright © 2022 Xie, Tang, Shi, Peng, Ye, Tao, Yu, Zheng and Chen. 2022 Xie, Tang, Shi, Peng, Ye, Tao, Yu, Zheng and Chen |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.3389/fphar.2022.853011 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Xie et al |
EISSN | 1663-9812 |
ExternalDocumentID | oai_doaj_org_article_408a61cacdb1479bb9af5a3027ca88f4 PMC8959572 35355730 10_3389_fphar_2022_853011 |
Genre | Journal Article Review |
GrantInformation_xml | – fundername: ; |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM IAO IEA IHR IHW IPNFZ NPM RIG 7X8 5PM |
ID | FETCH-LOGICAL-c465t-ece6f7702ad6c72bbed005b6a0a2ab7c477670757a2b6678900982fe5d4a64c93 |
IEDL.DBID | M48 |
ISSN | 1663-9812 |
IngestDate | Wed Aug 27 01:03:38 EDT 2025 Thu Aug 21 18:45:40 EDT 2025 Fri Jul 11 13:41:39 EDT 2025 Thu Jan 02 22:55:35 EST 2025 Thu Apr 24 23:04:59 EDT 2025 Tue Jul 01 03:27:56 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | component network meta-analysis disaccharides and polyols irritable bowel syndrome low fermentable oligosaccharides monosaccharides systematic review probiotics |
Language | English |
License | Copyright © 2022 Xie, Tang, Shi, Peng, Ye, Tao, Yu, Zheng and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c465t-ece6f7702ad6c72bbed005b6a0a2ab7c477670757a2b6678900982fe5d4a64c93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology Edited by: Raffaele Capasso, University of Naples Federico II, Italy These authors have contributed equally to this work Reviewed by: Chris Probert, University of Liverpool, United Kingdom Isabelle Mack, University of Tübingen, Germany |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2022.853011 |
PMID | 35355730 |
PQID | 2645856184 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_408a61cacdb1479bb9af5a3027ca88f4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8959572 proquest_miscellaneous_2645856184 pubmed_primary_35355730 crossref_primary_10_3389_fphar_2022_853011 crossref_citationtrail_10_3389_fphar_2022_853011 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-03-09 |
PublicationDateYYYYMMDD | 2022-03-09 |
PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-09 day: 09 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in pharmacology |
PublicationTitleAlternate | Front Pharmacol |
PublicationYear | 2022 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Jafari (B41) 2014; 17 Staudacher (B91) 2012; 142 Eswaran (B23) 2016; 111 Guglielmetti (B35) 2011; 33 Pineton de Chambrun (B73) 2015; 47 Buono (B10) 2017; 15 Lorenzo-Zuniga (B57) 2014; 20 Yoon (B103) 2015; 57 Black (B6) 2020; 69 Drossman (B19) 2016; 150 Martoni (B61) 2020; 12 Gayathri (B33) 2020; 35 Li (B55) 2020; 11 Frändemark (B31) 2018; 113 Sterne (B93) 2019; 366 Dapoigny (B16) 2012; 18 Ludidi (B58) 2014; 26 Ford (B25) 2018; 48 Ko (B49) 2013; 2013 Simren (B84) 2010; 31 Kim (B46) 2005; 17 Sadrin (B81) 2020; 52 Spiller (B90) 2016; 4 Oh (B70) 2019; 11 Chumpitazi (B14) 2015; 42 Sisson (B86) 2014; 40 Su (B95) 2020; 159 Charbonneau (B12) 2013; 4 Ford (B27); 109 Murakami (B65) 2012; 6 Roberts (B76) 2013; 13 McIntosh (B62) 2017; 66 Thijssen (B97) 2016; 28 Lewis (B54) 2020; 12 Kajander (B42) 2005; 22 Nobaek (B69) 2000; 95 Schumann (B82) 2018; 45 Francis (B30) 1997; 11 Madempudi (B60) 2019; 9 Enck (B22) 2009; 47 Guyonnet (B36) 2007; 26 Wilson (B101) 2020; 115 Sinn (B85) 2008; 53 Rücker (B80) 2020; 62 Wong (B102) 2015; 60 Dionne (B18) 2018; 113 Kim (B48) 2006; 47 Sperber (B89) 2021; 160 Barraza-Ortiz (B4) 2021; 39 Ford (B28); 109 Hod (B37) 2017; 29 Le Morvan de Sequeira (B53) 2021; 10 Su (B96) 2019; 42 Ford (B29) 2020; 396 Gade (B32) 1989; 7 Drouault-Holowacz (B20) 2008; 32 Black (B7) 2021 Kim (B45) 2003; 17 Shin (B83) 2018; 62 Pinto-Sanchez (B74) 2017; 153 Ringel-Kulka (B75) 2011; 45 Kajander (B43) 2008; 27 Andresen (B3) 2020; 5 Goyal (B34) 2021; 36 Farup (B24) 2012; 2012 Irvine (B40) 2016; 150 Catinean (B11) 2019; 11 Staudacher (B92) 2017; 153 Pedersen (B72) 2014; 20 Lyra (B59) 2016; 22 Begtrup (B5) 2013; 48 Hong (B38) 2009; 3 Lacy (B52) 2021; 116 Lacy (B51) 2016; 150 Niedzielin (B66) 2001; 13 Brignardello-Petersen (B9) 2020; 371 Böhn (B8) 2015; 149 Sondergaard (B88) 2011; 46 Whorwell (B99) 2006; 101 Ford (B26) 2017; 376 van Lanen (B98) 2021; 60 Niu (B67) 2020; 75 Rücker (B79) 2021; 63 Kruis (B50) 2012; 27 Agrawal (B2) 2009; 29 Zeng (B105) 2008; 28 Cui (B15) 2012; 5 Mearin (B63) 2004; 99 Williams (B100) 2009; 29 Ki Cha (B44) 2012; 46 Ducrotté (B21) 2012; 18 Niv (B68) 2005; 24 Abbas (B1) 2014; 26 Rogha (B77) 2014; 7 Liang (B56) 2019; 98 Yoon (B104) 2014; 29 Rücker (B78) 2012; 3 Stevenson (B94) 2014; 30 Kim (B47) 2020; 29 Patcharatrakul (B71) 2019; 11 Skrzydło-Radomańska (B87) 2021; 13 Darvishmoghadam (B17) 2019; 45 Hun (B39) 2009; 121 Choi (B13) 2011; 45 Michail (B64) 2011; 3 |
References_xml | – volume: 366 start-page: l4898 year: 2019 ident: B93 article-title: RoB 2: a Revised Tool for Assessing Risk of Bias in Randomised Trials publication-title: BMJ (Clinical research ed.) doi: 10.1136/bmj.l4898 – volume: 29 start-page: 837 year: 2020 ident: B47 article-title: Probiotic Treatment Induced Change of Inflammation Related Metabolites in IBS-D Patients/double-Blind, Randomized, Placebo-Controlled Trial publication-title: Food Sci. Biotechnol. doi: 10.1007/s10068-019-00717-2 – volume: 33 start-page: 1123 year: 2011 ident: B35 article-title: Randomised Clinical Trial: Bifidobacterium Bifidum MIMBb75 Significantly Alleviates Irritable Bowel Syndrome and Improves Quality of Life-Aa Double-Blind, Placebo-Controlled Study publication-title: Aliment. Pharmacol. Ther. doi: 10.1111/j.1365-2036.2011.04633.x – volume: 29 start-page: 104 year: 2009 ident: B2 article-title: Clinical Trial: The Effects of a Fermented Milk Product Containing Bifidobacterium Lactis DN-173 010 on Abdominal Distension and Gastrointestinal Transit in Irritable Bowel Syndrome with Constipation publication-title: Aliment. Pharmacol. Ther. doi: 10.1111/j.1365-2036.2008.03853.x – volume: 20 start-page: 8709 year: 2014 ident: B57 article-title: I.31, a New Combination of Probiotics, Improves Irritable Bowel Syndrome-Related Quality of Life publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v20.i26.8709 – volume: 13 start-page: 45 year: 2013 ident: B76 article-title: A Randomised Controlled Trial of a Probiotic “Functional Food” in the Management of Irritable Bowel Syndrome publication-title: BMC Gastroenterol. doi: 10.1186/1471-230X-13-45 – volume: 18 start-page: 2067 year: 2012 ident: B16 article-title: Efficacy and Safety Profile of LCR35 Complete Freeze-Dried Culture in Irritable Bowel Syndrome: a Randomized, Double-Blind Study publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v18.i17.2067 – volume: 98 start-page: e16068 year: 2019 ident: B56 article-title: Efficacy of Different Probiotic Protocols in Irritable Bowel Syndrome: A Network Meta-Analysis publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000016068 – volume: 11 start-page: 2887 year: 2019 ident: B70 article-title: Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial publication-title: Nutrients doi: 10.3390/nu11122887 – volume: 2013 start-page: 824605 year: 2013 ident: B49 article-title: Effect of Korean Herbal Medicine Combined with a Probiotic Mixture on Diarrhea-Dominant Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo-Controlled Trial publication-title: Evid.-Based Complement. Altern. Med. doi: 10.1155/2013/824605 – volume: 39 start-page: 294 year: 2021 ident: B4 article-title: Combination of a Probiotic and an Antispasmodic Increases Quality of Life and Reduces Symptoms in Patients with Irritable Bowel Syndrome: A Pilot Study publication-title: Dig. Dis. doi: 10.1159/000510950 – volume: 45 start-page: 24 year: 2018 ident: B82 article-title: Low Fermentable, Oligo-, Di-, Mono-Saccharides and Polyol Diet in the Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis publication-title: Nutrition doi: 10.1016/j.nut.2017.07.004 – volume: 5 start-page: 238 year: 2012 ident: B15 article-title: Multistrain Probiotic Preparation Significantly Reduces Symptoms of Irritable Bowel Syndrome in a Double-Blind Placebo-Controlled Study publication-title: Int. J. Clin. Exp. Med. – volume: 371 start-page: m3900 year: 2020 ident: B9 article-title: GRADE Approach to Drawing Conclusions from a Network Meta-Analysis Using a Minimally Contextualised Framework publication-title: BMJ doi: 10.1136/bmj.m3900 – volume: 45 start-page: 242 year: 2019 ident: B17 article-title: Assessment of the Effect of Sachet Formulation of almond (Amygdalus Dulcis L.) on Diarrhea Prominent Irritable Bowel Syndrome (IBS-D) Symptoms: A Clinical Trial publication-title: Complement. Ther. Med. doi: 10.1016/j.ctim.2019.07.001 – volume: 26 start-page: 705 year: 2014 ident: B58 article-title: Randomized Clinical Trial on the Effect of a Multispecies Probiotic on Visceroperception in Hypersensitive IBS Patients publication-title: Neurogastroenterol Motil. doi: 10.1111/nmo.12320 – volume: 115 start-page: 906 year: 2020 ident: B101 article-title: β-Galactooligosaccharide in Conjunction with Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria publication-title: Am. J. Gastroenterol. doi: 10.14309/ajg.0000000000000641 – volume: 150 start-page: 1257 year: 2016 ident: B19 article-title: Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.03.035 – volume: 53 start-page: 2714 year: 2008 ident: B85 article-title: Therapeutic Effect of Lactobacillus Acidophilus-SDC 2012, 2013 in Patients with Irritable Bowel Syndrome publication-title: Dig. Dis. Sci. doi: 10.1007/s10620-007-0196-4 – volume: 15 start-page: 35 year: 2017 ident: B10 article-title: Health-related Quality of Life, Work Productivity, and Indirect Costs Among Patients with Irritable Bowel Syndrome with Diarrhea publication-title: Health Qual. Life Outcomes doi: 10.1186/s12955-017-0611-2 – volume: 22 start-page: 387 year: 2005 ident: B42 article-title: A Probiotic Mixture Alleviates Symptoms in Irritable Bowel Syndrome Patients: a Controlled 6-month Intervention publication-title: Aliment. Pharmacol. Ther. doi: 10.1111/j.1365-2036.2005.02579.x – volume: 46 start-page: 220 year: 2012 ident: B44 article-title: The Effect of a Multispecies Probiotic Mixture on the Symptoms and Fecal Microbiota in Diarrhea-Dominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial publication-title: J. Clin. Gastroenterol. doi: 10.1097/MCG.0b013e31823712b1 – volume: 7 start-page: 23 year: 1989 ident: B32 article-title: Paraghurt for Patients with Irritable Bowel Syndrome. A Controlled Clinical Investigation from General Practice publication-title: Scand. J. Prim. Health Care doi: 10.3109/02813438909103666 – volume: 47 start-page: 413 year: 2006 ident: B48 article-title: The Effects of Probiotics on Symptoms of Irritable Bowel Syndrome publication-title: Korean J. Gastroenterol. – volume: 60 start-page: 3505 year: 2021 ident: B98 article-title: Efficacy of a Low-FODMAP Diet in Adult Irritable Bowel Syndrome: a Systematic Review and Meta-Analysis publication-title: Eur. J. Nutr. doi: 10.1007/s00394-020-02473-0 – volume: 47 start-page: 119 year: 2015 ident: B73 article-title: A Randomized Clinical Trial of Saccharomyces cerevisiae versus Placebo in the Irritable Bowel Syndrome publication-title: Dig. Liver Dis. doi: 10.1016/j.dld.2014.11.007 – volume: 150 start-page: 1393 year: 2016 ident: B51 article-title: Bowel Disorders publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.02.031 – volume: 48 start-page: 1127 year: 2013 ident: B5 article-title: Long-term Treatment with Probiotics in Primary Care Patients with Irritable Bowel Syndrome-Aa Randomised, Double-Blind, Placebo Controlled Trial publication-title: Scand. J. Gastroenterol. doi: 10.3109/00365521.2013.825314 – volume: 48 start-page: 1044 year: 2018 ident: B25 article-title: Systematic Review with Meta-Analysis: the Efficacy of Prebiotics, Probiotics, Synbiotics and Antibiotics in Irritable Bowel Syndrome publication-title: Aliment. Pharmacol. Ther. doi: 10.1111/apt.15001 – volume: 11 start-page: 395 year: 1997 ident: B30 article-title: The Irritable Bowel Severity Scoring System: a Simple Method of Monitoring Irritable Bowel Syndrome and its Progress publication-title: Aliment. Pharmacol. Ther. doi: 10.1046/j.1365-2036.1997.142318000.x – volume: 17 start-page: 895 year: 2003 ident: B45 article-title: A Randomized Controlled Trial of a Probiotic, VSL#3, on Gut Transit and Symptoms in Diarrhoea-Predominant Irritable Bowel Syndrome publication-title: Aliment. Pharmacol. Ther. doi: 10.1046/j.1365-2036.2003.01543.x – volume: 2012 start-page: 214102 year: 2012 ident: B24 article-title: Probiotics, Symptoms, and Gut Microbiota: What Are the Relations? A Randomized Controlled Trial in Subjects with Irritable Bowel Syndrome publication-title: Gastroenterol. Res. Pract. doi: 10.1155/2012/214102 – volume: 113 start-page: 1290 year: 2018 ident: B18 article-title: A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-free Diet and a Low FODMAP Diet in Treating Symptoms of Irritable Bowel Syndrome publication-title: Am. J. Gastroenterol. doi: 10.1038/s41395-018-0195-4 – volume: 11 start-page: 332 year: 2020 ident: B55 article-title: Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis publication-title: Front. Pharmacol. doi: 10.3389/fphar.2020.00332 – volume: 159 start-page: 697 year: 2020 ident: B95 article-title: AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.05.059 – volume: 153 start-page: 936 year: 2017 ident: B92 article-title: A Diet Low in FODMAP Reduces Symptoms in Patients with Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial publication-title: Gastroenterology doi: 10.1053/j.gastro.2017.06.010 – volume: 32 start-page: 147 year: 2008 ident: B20 article-title: A Double Blind Randomized Controlled Trial of a Probiotic Combination in 100 Patients with Irritable Bowel Syndrome publication-title: Gastroenterol. Clin. Biol. doi: 10.1016/j.gcb.2007.06.001 – volume: 113 start-page: 1540 year: 2018 ident: B31 article-title: Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem publication-title: Am. J. Gastroenterol. doi: 10.1038/s41395-018-0262-x – volume: 75 start-page: 116 year: 2020 ident: B67 article-title: The Efficacy and Safety of Probiotics in Patients with Irritable Bowel Syndrome: Evidence Based on 35 Randomized Controlled Trials publication-title: Int. J. Surg. doi: 10.1016/j.ijsu.2020.01.142 – volume: 150 start-page: 1469 year: 2016 ident: B40 article-title: Design of Treatment Trials for Functional Gastrointestinal Disorders publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.02.010 – volume: 101 start-page: 1581 year: 2006 ident: B99 article-title: Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Women with Irritable Bowel Syndrome publication-title: Am. J. Gastroenterol. doi: 10.1111/j.1572-0241.2006.00734.x – volume: 29 start-page: e13037 year: 2017 ident: B37 article-title: A Double-Blind, Placebo-Controlled Study to Assess the Effect of a Probiotic Mixture on Symptoms and Inflammatory Markers in Women with Diarrhea-Predominant IBS publication-title: Neurogastroenterol Motil. doi: 10.1111/nmo.13037 – volume: 153 start-page: 448 year: 2017 ident: B74 article-title: Probiotic Bifidobacterium Longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients with Irritable Bowel Syndrome publication-title: Gastroenterology doi: 10.1053/j.gastro.2017.05.003 – volume: 52 start-page: 534 year: 2020 ident: B81 article-title: A 2-strain Mixture of Lactobacillus Acidophilus in the Treatment of Irritable Bowel Syndrome: A Placebo-Controlled Randomized Clinical Trial publication-title: Dig. Liver Dis. doi: 10.1016/j.dld.2019.12.009 – volume: 11 start-page: 1968 year: 2019 ident: B11 article-title: Bacillus Spp. Spores-A Promising Treatment Option for Patients with Irritable Bowel Syndrome publication-title: Nutrients doi: 10.3390/nu11091968 – volume: 13 start-page: 756 year: 2021 ident: B87 article-title: The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study publication-title: Nutrients doi: 10.3390/nu13030756 – volume: 109 start-page: 1350 ident: B27 article-title: Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis publication-title: Am. J. Gastroenterol. doi: 10.1038/ajg.2014.148 – volume: 121 start-page: 119 year: 2009 ident: B39 article-title: Bacillus Coagulans Significantly Improved Abdominal Pain and Bloating in Patients with IBS publication-title: Postgrad. Med. doi: 10.3810/pgm.2009.03.1984 – volume: 9 start-page: 12210 year: 2019 ident: B60 article-title: Randomized Clinical Trial: the Effect of Probiotic Bacillus Coagulans Unique IS2 vs. Placebo on the Symptoms Management of Irritable Bowel Syndrome in Adults publication-title: Sci. Rep. doi: 10.1038/s41598-019-48554-x – volume: 7 start-page: 156 year: 2014 ident: B77 article-title: The Efficacy of a Synbiotic Containing Bacillus Coagulans in Treatment of Irritable Bowel Syndrome: a Randomized Placebo-Controlled Trial publication-title: Gastroenterol. Hepatol. Bed Bench – volume: 63 start-page: 447 year: 2021 ident: B79 article-title: Component Network Meta-Analysis Compared to a Matching Method in a Disconnected Network: A Case Study publication-title: Biometrical Journal. Biometrische Z. doi: 10.1002/bimj.201900339 – volume: 36 start-page: 2107 year: 2021 ident: B34 article-title: Low Fermentable Oligosaccharide, Disaccharide, Monosaccharide, and Polyol Diet in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Prospective, Randomized Trial publication-title: J. Gastroenterol. Hepatol. doi: 10.1111/jgh.15410 – volume: 22 start-page: 10631 year: 2016 ident: B59 article-title: Irritable Bowel Syndrome Symptom Severity Improves Equally with Probiotic and Placebo publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v22.i48.10631 – volume: 396 start-page: 1675 year: 2020 ident: B29 article-title: Irritable Bowel Syndrome publication-title: Lancet doi: 10.1016/S0140-6736(20)31548-8 – volume: 29 start-page: 52 year: 2014 ident: B104 article-title: Effect of Multispecies Probiotics on Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial publication-title: J. Gastroenterol. Hepatol. doi: 10.1111/jgh.12322 – volume: 6 start-page: 16 year: 2012 ident: B65 article-title: The Effect of Lactobacillus Brevis KB290 against Irritable Bowel Syndrome: a Placebo-Controlled Double-Blind Crossover Trial publication-title: Biopsychosoc Med. doi: 10.1186/1751-0759-6-16 – volume: 42 start-page: 418 year: 2015 ident: B14 article-title: Randomised Clinical Trial: Gut Microbiome Biomarkers Are Associated with Clinical Response to a Low FODMAP Diet in Children with the Irritable Bowel Syndrome publication-title: Aliment. Pharmacol. Ther. doi: 10.1111/apt.13286 – volume: 27 start-page: 48 year: 2008 ident: B43 article-title: Clinical Trial: Multispecies Probiotic Supplementation Alleviates the Symptoms of Irritable Bowel Syndrome and Stabilizes Intestinal Microbiota publication-title: Aliment. Pharmacol. Ther. doi: 10.1111/j.1365-2036.2007.03542.x – volume: 27 start-page: 467 year: 2012 ident: B50 article-title: A Double-Blind Placebo-Controlled Trial to Study Therapeutic Effects of Probiotic Escherichia coli Nissle 1917 in Subgroups of Patients with Irritable Bowel Syndrome publication-title: Int. J. Colorectal Dis. doi: 10.1007/s00384-011-1363-9 – volume: 12 start-page: 363 year: 2020 ident: B61 article-title: Lactobacillus Acidophilus DDS-1 and Bifidobacterium Lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial publication-title: Nutrients doi: 10.3390/nu12020363 – volume: 18 start-page: 4012 year: 2012 ident: B21 article-title: Clinical Trial: Lactobacillus Plantarum 299v (DSM 9843) Improves Symptoms of Irritable Bowel Syndrome publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v18.i30.4012 – volume: 20 start-page: 16215 year: 2014 ident: B72 article-title: Ehealth: Low FODMAP Diet vs Lactobacillus Rhamnosus GG in Irritable Bowel Syndrome publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v20.i43.16215 – volume: 17 start-page: 687 year: 2005 ident: B46 article-title: A Randomized Controlled Trial of a Probiotic Combination VSL# 3 and Placebo in Irritable Bowel Syndrome with Bloating publication-title: Neurogastroenterol Motil. doi: 10.1111/j.1365-2982.2005.00695.x – volume: 26 start-page: 630 year: 2014 ident: B1 article-title: Cytokine and Clinical Response to Saccharomyces Boulardii Therapy in Diarrhea-Dominant Irritable Bowel Syndrome: A Randomized Trial publication-title: Eur. J. Gastroenterol. Hepatol. doi: 10.1097/MEG.0000000000000094 – volume: 60 start-page: 186 year: 2015 ident: B102 article-title: Melatonin Regulation as a Possible Mechanism for Probiotic (VSL#3) in Irritable Bowel Syndrome: a Randomized Double-Blinded Placebo Study publication-title: Dig. Dis. Sci. doi: 10.1007/s10620-014-3299-8 – volume: 66 start-page: 1241 year: 2017 ident: B62 article-title: FODMAP Alter Symptoms and the Metabolome of Patients with IBS: a Randomised Controlled Trial publication-title: Gut doi: 10.1136/gutjnl-2015-311339 – volume: 3 start-page: 1 year: 2011 ident: B64 article-title: Gut Microbiota Is Not Modified by Randomized, Double-Blind, Placebo-Controlled Trial of VSL#3 in Diarrhea-Predominant Irritable Bowel Syndrome publication-title: Probiotics Antimicrob. Proteins doi: 10.1007/s12602-010-9059-y – volume: 13 start-page: 1143 year: 2001 ident: B66 article-title: A Controlled, Double-Blind, Randomized Study on the Efficacy of Lactobacillus Plantarum 299V in Patients with Irritable Bowel Syndrome publication-title: Eur. J. Gastroenterol. Hepatol. doi: 10.1097/00042737-200110000-00004 – volume: 4 start-page: 201 year: 2013 ident: B12 article-title: Fecal Excretion of Bifidobacterium Infantis 35624 and Changes in Fecal Microbiota after Eight Weeks of Oral Supplementation with Encapsulated Probiotic publication-title: Gut Microbes doi: 10.4161/gmic.24196 – volume: 28 start-page: 8 year: 2016 ident: B97 article-title: Efficacy of Lactobacillus Casei Shirota for Patients with Irritable Bowel Syndrome publication-title: Eur. J. Gastroenterol. Hepatol. doi: 10.1097/MEG.0000000000000484 – volume: 11 start-page: 2856 year: 2019 ident: B71 article-title: Effect of Structural Individual Low-FODMAP Dietary Advice vs. Brief Advice on a Commonly Recommended Diet on IBS Symptoms and Intestinal Gas Production publication-title: Nutrients doi: 10.3390/nu11122856 – volume: 62 start-page: 808 year: 2020 ident: B80 article-title: Network Meta-Analysis of Multicomponent Interventions publication-title: Biom J. doi: 10.1002/bimj.201800167 – volume: 35 start-page: 139 year: 2020 ident: B33 article-title: Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an Add-On Therapy for Irritable Bowel Syndrome publication-title: Int. J. Colorectal Dis. doi: 10.1007/s00384-019-03462-4 – volume: 57 start-page: 129 year: 2015 ident: B103 article-title: Effect of Administering a Multi-Species Probiotic Mixture on the Changes in Fecal Microbiota and Symptoms of Irritable Bowel Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial publication-title: J. Clin. Biochem. Nutr. doi: 10.3164/jcbn.15-14 – year: 2021 ident: B7 article-title: Efficacy of a Low FODMAP Diet in Irritable Bowel Syndrome: Systematic Review and Network Meta-Analysis publication-title: Gut doi: 10.1136/gutjnl-2021-325214 – volume: 47 start-page: 209 year: 2009 ident: B22 article-title: Randomized Controlled Treatment Trial of Irritable Bowel Syndrome with a Probiotic E.-coli Preparation (DSM17252) Compared to Placebo publication-title: Z. Gastroenterol. doi: 10.1055/s-2008-1027702 – volume: 29 start-page: 97 year: 2009 ident: B100 article-title: Clinical Trial: A Multistrain Probiotic Preparation Significantly Reduces Symptoms of Irritable Bowel Syndrome in a Double-Blind Placebo-Controlled Study publication-title: Aliment. Pharmacol. Ther. doi: 10.1111/j.1365-2036.2008.03848.x – volume: 3 start-page: 101 year: 2009 ident: B38 article-title: Effect of Probiotics on Symptoms in Korean Adults with Irritable Bowel Syndrome publication-title: Gut Liver doi: 10.5009/gnl.2009.3.2.101 – volume: 62 start-page: 179 year: 2018 ident: B83 article-title: A Double Blind, Placebo-Controlled, Randomized Clinical Trial that Breast Milk Derived-Lactobacillus Gasseri BNR17 Mitigated Diarrhea-Dominant Irritable Bowel Syndrome publication-title: J. Clin. Biochem. Nutr. doi: 10.3164/jcbn.17-73 – volume: 28 start-page: 994 year: 2008 ident: B105 article-title: Clinical Trial: Effect of Active Lactic Acid Bacteria on Mucosal Barrier Function in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome publication-title: Aliment. Pharmacol. Ther. doi: 10.1111/j.1365-2036.2008.03818.x – volume: 142 start-page: 1510 year: 2012 ident: B91 article-title: Fermentable Carbohydrate Restriction Reduces Luminal Bifidobacteria and Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome publication-title: J. Nutr. doi: 10.3945/jn.112.159285 – volume: 45 start-page: 679 year: 2011 ident: B13 article-title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of saccharomyces Boulardii in Irritable Bowel Syndrome: Effect on Quality of Life publication-title: J. Clin. Gastroenterol. doi: 10.1097/MCG.0b013e318204593e – volume: 116 start-page: 17 year: 2021 ident: B52 article-title: ACG Clinical Guideline: Management of Irritable Bowel Syndrome publication-title: Am. J. Gastroenterol. doi: 10.14309/ajg.0000000000001036 – volume: 24 start-page: 925 year: 2005 ident: B68 article-title: The Efficacy of Lactobacillus Reuteri ATCC 55730 in the Treatment of Patients with Irritable Bowel Syndrome - A Double Blind, Placebo-Controlled, Randomized Study publication-title: Clin. Nutr. doi: 10.1016/j.clnu.2005.06.001 – volume: 376 start-page: 2566 year: 2017 ident: B26 article-title: Irritable Bowel Syndrome publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1607547 – volume: 5 start-page: 658 year: 2020 ident: B3 article-title: Heat-inactivated Bifidobacterium Bifidum MIMBb75 (SYN-HI-001) in the Treatment of Irritable Bowel Syndrome: a Multicentre, Randomised, Double-Blind, Placebo-Controlled Clinical Trial publication-title: Lancet Gastroenterol. Hepatol. doi: 10.1016/S2468-1253(20)30056-X – volume: 10 start-page: 3497 year: 2021 ident: B53 article-title: The Effect of Probiotics on Quality of Life, Depression and Anxiety in Patients with Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis publication-title: J. Clin. Med. doi: 10.3390/jcm10163497 – volume: 3 start-page: 312 year: 2012 ident: B78 article-title: Network Meta-Analysis, Electrical Networks and Graph Theory publication-title: Res. Synth. Methods doi: 10.1002/jrsm.1058 – volume: 109 start-page: 1547 ident: B28 article-title: Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-Analysis publication-title: Am. J. Gastroenterol. doi: 10.1038/ajg.2014.202 – volume: 40 start-page: 51 year: 2014 ident: B86 article-title: Randomised Clinical Trial: A Liquid Multi-Strain Probiotic vs. Placebo in the Irritable Bowel Syndrome–A 12 Week Double-Blind Study publication-title: Aliment. Pharmacol. Ther. doi: 10.1111/apt.12787 – volume: 111 start-page: 1824 year: 2016 ident: B23 article-title: A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D publication-title: Am. J. Gastroenterol. doi: 10.1038/ajg.2016.434 – volume: 160 start-page: 99 year: 2021 ident: B89 article-title: Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.04.014 – volume: 149 start-page: 1399 year: 2015 ident: B8 article-title: Diet Low in FODMAP Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.07.054 – volume: 30 start-page: 1151 year: 2014 ident: B94 article-title: Randomized Clinical Trial: Effect of Lactobacillus Plantarum 299 V on Symptoms of Irritable Bowel Syndrome publication-title: Nutrition doi: 10.1016/j.nut.2014.02.010 – volume: 17 start-page: 466 year: 2014 ident: B41 article-title: Therapeutic Effects, Tolerability and Safety of a Multi-Strain Probiotic in Iranian Adults with Irritable Bowel Syndrome and Bloating publication-title: Arch. Iranian Med. – volume: 99 start-page: 122 year: 2004 ident: B63 article-title: Splitting Irritable Bowel Syndrome: from Original Rome to Rome II Criteria publication-title: Am. J. Gastroenterol. doi: 10.1046/j.1572-0241.2003.04024.x – volume: 26 start-page: 475 year: 2007 ident: B36 article-title: Effect of a Fermented Milk Containing Bifidobacterium Animalis DN-173 010 on the Health-Related Quality of Life and Symptoms in Irritable Bowel Syndrome in Adults in Primary Care: a Multicentre, Randomized, Double-Blind, Controlled Trial publication-title: Aliment. Pharmacol. Ther. doi: 10.1111/j.1365-2036.2007.03362.x – volume: 4 start-page: 353 year: 2016 ident: B90 article-title: Randomized Double Blind Placebo-Controlled Trial of Saccharomyces cerevisiae CNCM I-3856 in Irritable Bowel Syndrome: Improvement in Abdominal Pain and Bloating in Those with Predominant Constipation publication-title: United Eur. Gastroenterol. J. doi: 10.1177/2050640615602571 – volume: 31 start-page: 218 year: 2010 ident: B84 article-title: Clinical Trial: the Effects of a Fermented Milk Containing Three Probiotic Bacteria in Patients with Irritable Bowel Syndrome - a Randomized, Double-Blind, Controlled Study publication-title: Aliment. Pharmacol. Ther. doi: 10.1111/j.1365-2036.2009.04183.x – volume: 12 start-page: 1159 year: 2020 ident: B54 article-title: Efficacy of Lactobacillus Paracasei Ha-196 and Bifidobacterium Longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study publication-title: Nutrients doi: 10.3390/nu12041159 – volume: 45 start-page: 518 year: 2011 ident: B75 article-title: Probiotic Bacteria Lactobacillus Acidophilus NCFM and Bifidobacterium Lactis Bi-07 versus Placebo for the Symptoms of Bloating in Patients with Functional Bowel Disorders: a Double-Blind Study publication-title: J. Clin. Gastroenterol. doi: 10.1097/MCG.0b013e31820ca4d6 – volume: 46 start-page: 663 year: 2011 ident: B88 article-title: Effects of Probiotic Fermented Milk on Symptoms and Intestinal flora in Patients with Irritable Bowel Syndrome: a Randomized, Placebo-Controlled Trial publication-title: Scand. J. Gastroenterol. doi: 10.3109/00365521.2011.565066 – volume: 69 start-page: 74 year: 2020 ident: B6 article-title: Efficacy of Pharmacological Therapies in Patients with IBS with Diarrhoea or Mixed Stool Pattern: Systematic Review and Network Meta-Analysis publication-title: Gut doi: 10.1136/gutjnl-2018-318160 – volume: 95 start-page: 1231 year: 2000 ident: B69 article-title: Alteration of Intestinal Microflora Is Associated with Reduction in Abdominal Bloating and Pain in Patients with Irritable Bowel Syndrome publication-title: Am. J. Gastroenterol. doi: 10.1111/j.1572-0241.2000.02015.x – volume: 42 start-page: 150 year: 2019 ident: B96 article-title: Effects of Low-FODMAP Diet on Irritable Bowel Syndrome Symptoms and Gut Microbiome publication-title: Gastroenterol. Nurs. doi: 10.1097/SGA.0000000000000428 |
SSID | ssj0000399364 |
Score | 2.3559895 |
SecondaryResourceType | review_article |
Snippet | Background:
Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches... Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches for patients... Background: Probiotic and low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet are two commonly used management approaches... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 853011 |
SubjectTerms | and polyols disaccharides irritable bowel syndrome low fermentable oligosaccharides monosaccharides Pharmacology probiotics |
SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ1LT9wwEICtihOXqu-mtNVUQhwqUryO48S9LdAVrbp0JUDlZo0f0W61yiIIQvz7-hGW3aoql14TW7E8Y89MZvyZkG0jma14afPGNDb3ux_NNS147i0fl4W0Glk47zw-Fkdn_Nt5eb5y1VeoCUt44DRxe5zWKAYGjdUDXkmtJTYlhmybwbpuIgnU27yVYCruwcHuCp7SmD4Kk3vNxRQD_5OxT95C0cFgzRBFXv_fnMw_ayVXjM_oCXnce40wTKN9Sh659hnZmSTs9O0unN6forrahR2Y3AOpb5-TX98XNzD6cTgeTuBw5jrA1sIkAphCB5i18PUy_CTQcwf7ixs3h5MeZPAZhnCyhD1DyiTAz1k3heNUQA5j12GOPdvkBTkbfTk9OMr7OxZyw0XZ5c440VQVZWiFqZjWzvp1qQVSZKgrwwPtx7sVFTItRDg1S2XNGldajoIbWbwkG-2ida8JOMsLatF7ZBi6GSyE8AET1bbERvIiI_RuwpXpAeThHoy58oFIkJGKMlJBRirJKCMfl10uEn3jX433gxSXDQM4Oz7w6qR6dVIPqVNGPtzpgPILLWRPsHWL6yvlPUcfWoX7cTLyKunE8lNF6d02v1dmpFrTlrWxrL9pZ9MI865lKcuKvfkfg98im2E-YomcfEs2ustr9877TJ1-H5fHb0tCFtg priority: 102 providerName: Directory of Open Access Journals |
Title | Low FODMAP Diet and Probiotics in Irritable Bowel Syndrome: A Systematic Review With Network Meta-analysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35355730 https://www.proquest.com/docview/2645856184 https://pubmed.ncbi.nlm.nih.gov/PMC8959572 https://doaj.org/article/408a61cacdb1479bb9af5a3027ca88f4 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELem8cIL4pvwMRkJ7QEtI3UcO0ZCqGNUA9FRaavYW3T-CC2qktFmGv3v8TlpR1GFeE3iOPH5_Lvz-X5HyCujmJU8s3FpShv71S-JdZLy2CMfV6myGhjmOw9PxcmYf77ILnbIqrxVN4CLra4d1pMaz2eHv34u33uFf4cep8fbN-XlBJDak7FDDz4JZvre8sAksaDBsLP2w8KMYBwIpXoeZ2Plsa2Nc25_ywZSBUL_bVbo34cp_0CnwV1ypzMrab-dB_fIjqvuk_1Ry0u9PKDnN2lWiwO6T0c3jNXLB-THl_qaDr4eD_sjejx1DYXK0lFgaMIGdFrRT3PcRdAzR4_qazejZx3TwVvap2drNmjahhrot2kzoaftCXM6dA3E0JGfPCTjwcfzDydxV4QhNlxkTeyME6WUCQMrjGRaO-sVVwtIgIGWhiMdkLc7JDAtBKbVJipnpcssB8GNSh-R3aqu3BNCneVpYsGbbIDNDKRCeI8q0TaDUvE0IslqwAvTMZRjoYxZ4T0VlFERZFSgjIpWRhF5vW5y2dJz_OvhI5Ti-kFk1g4X6vn3olPUgic5iJ4BY3WPS6W1gjIDjO4ayPOSR-Tlag4UXhMxvAKVq68WhTctve-FBXQi8ridE-uu0szbdX4xjYjcmC0b37J5p5pOAtt3rjKVSfb0P_p9Rm7j74Yjcuo52W3mV-6Ft5kavRf2GvaCPvwGMt0WRg |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low+FODMAP+Diet+and+Probiotics+in+Irritable+Bowel+Syndrome%3A+A+Systematic+Review+With+Network+Meta-analysis&rft.jtitle=Frontiers+in+pharmacology&rft.au=Xie%2C+Chao-Rong&rft.au=Tang%2C+Bin&rft.au=Shi%2C+Yun-Zhou&rft.au=Peng%2C+Wen-Yan&rft.date=2022-03-09&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=13&rft.spage=853011&rft_id=info:doi/10.3389%2Ffphar.2022.853011&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |